Literature DB >> 27067082

Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft.

Zhaoying Yang1,2, Le Zhang1,2, Stefano Serra2,3, Calvin Law4,5, Alice Wei2,5, Tracy L Stockley2,3, Shereen Ezzat2,6, Sylvia L Asa7,8,9.   

Abstract

Neuroendocrine tumors (NETs) are increasing in incidence yet the cause of these tumors remains unknown. Familial associations have shed light on the genetic basis of some of these tumors, but sporadic tumors seem to have primarily epigenetic dysregulation. The rarity of cell lines and animal models has been a barrier to studies of treatment modalities. We set out to develop a xenograft model of gastrointestinal NETs. Primary human NETs were collected at the time of surgery under sterile conditions and xenografted into the flanks of immunodeficient mice. Tumor growth was measured and when tumors reached 1500 mm(3), they were excised and half was re-xenografted through multiple generations. The other half was bisected; a part was frozen and a part was fixed for morphologic and immunohistochemical characterization as well as molecular validation of fidelity of a successful xenograft. Of 106 human NETs, seven were successfully engrafted of which only one tumor was successfully propagated for eight passages. Two years later, the tumor retains its neuroendocrine features and similarity to the original primary human tumor. It has retained expression of keratin as well as chromogranin A reactivity. The establishment of a NET xenograft provides a model for further study of the biological behavior of these tumors and can be used to examine the in vivo effects of various medical and targeted radiotherapeutic agents on tumor growth.

Entities:  

Keywords:  Cell lines; Mouse model; Neuroendocrine tumor; Xenograft

Mesh:

Year:  2016        PMID: 27067082     DOI: 10.1007/s12022-016-9429-4

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  11 in total

1.  Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.

Authors:  Anna Karlsson; Mats Jönsson; Martin Lauss; Hans Brunnström; Per Jönsson; Åke Borg; Göran Jönsson; Markus Ringnér; Maria Planck; Johan Staaf
Journal:  Clin Cancer Res       Date:  2014-10-02       Impact factor: 12.531

Review 2.  Animal models and cell lines of pancreatic neuroendocrine tumors.

Authors:  Varsha Babu; Navin Paul; Run Yu
Journal:  Pancreas       Date:  2013-08       Impact factor: 3.327

3.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

4.  Spectral karyotypic and comparative genomic analysis of the endocrine pancreatic tumor cell line BON-1.

Authors:  Juan R Lopez; Sandra M H Claessen; Merryn V E Macville; Jozefa C M Albrechts; Britt Skogseid; Ernst-Jan M Speel
Journal:  Neuroendocrinology       Date:  2009-10-29       Impact factor: 4.914

5.  Genetic and epigenetic alterations of the APC gene in malignant melanoma.

Authors:  Jesper Worm; Claus Christensen; Kirsten Grønbaek; Eugene Tulchinsky; Per Guldberg
Journal:  Oncogene       Date:  2004-07-01       Impact factor: 9.867

6.  The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.

Authors:  Stefano Serra; Lei Zheng; Manal Hassan; Alexandria T Phan; Linda J Woodhouse; James C Yao; Shereen Ezzat; Sylvia L Asa
Journal:  Cancer Res       Date:  2012-09-17       Impact factor: 12.701

7.  QGP-1 cells release 5-HT via TRPA1 activation; a model of human enterochromaffin cells.

Authors:  Hitoshi Doihara; Katsura Nozawa; Ryosuke Kojima; Eri Kawabata-Shoda; Toshihide Yokoyama; Hiroyuki Ito
Journal:  Mol Cell Biochem       Date:  2009-06-09       Impact factor: 3.396

8.  Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor.

Authors:  Anna Karpathakis; Harpreet Dibra; Chistodoulos Pipinikas; Andrew Feber; Tiffany Morris; Joshua Francis; Dahmane Oukrif; Dalvinder Mandair; Marinos Pericleous; Mullan Mohmaduvesh; Stefano Serra; Olagunju Ogunbiyi; Marco Novelli; TuVinh Luong; Sylvia L Asa; Matthew Kulke; Christos Toumpanakis; Tim Meyer; Martyn Caplin; Matthew Meyerson; Stephan Beck; Christina Thirlwell
Journal:  Clin Cancer Res       Date:  2015-07-13       Impact factor: 12.531

9.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

10.  Somatic mutation of CDKN1B in small intestine neuroendocrine tumors.

Authors:  Joshua M Francis; Adam Kiezun; Alex H Ramos; Stefano Serra; Chandra Sekhar Pedamallu; Zhi Rong Qian; Michaela S Banck; Rahul Kanwar; Amit A Kulkarni; Anna Karpathakis; Veronica Manzo; Tanupriya Contractor; Juliet Philips; Elizabeth Nickerson; Nam Pho; Susanne M Hooshmand; Lauren K Brais; Michael S Lawrence; Trevor Pugh; Aaron McKenna; Andrey Sivachenko; Kristian Cibulskis; Scott L Carter; Akinyemi I Ojesina; Samuel Freeman; Robert T Jones; Douglas Voet; Gordon Saksena; Daniel Auclair; Robert Onofrio; Erica Shefler; Carrie Sougnez; Jonna Grimsby; Lisa Green; Niall Lennon; Tim Meyer; Martyn Caplin; Daniel C Chung; Andreas S Beutler; Shuji Ogino; Christina Thirlwell; Ramesh Shivdasani; Sylvia L Asa; Chris R Harris; Gad Getz; Matthew Kulke; Matthew Meyerson
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

View more
  5 in total

Review 1.  Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets.

Authors:  Chandra K Maharjan; Po Hien Ear; Catherine G Tran; James R Howe; Chandrikha Chandrasekharan; Dawn E Quelle
Journal:  Cancers (Basel)       Date:  2021-10-12       Impact factor: 6.639

Review 2.  Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models.

Authors:  Kenta Kawasaki; Masayuki Fujii; Toshiro Sato
Journal:  Dis Model Mech       Date:  2018-02-26       Impact factor: 5.758

3.  Ex Vivo Modeling of Human Neuroendocrine Tumors in Tissue Surrogates.

Authors:  Brendon Herring; Samuel Jang; Jason Whitt; Kayla Goliwas; Zviadi Aburjania; Vikas Dudeja; Bin Ren; Joel Berry; James Bibb; Andra Frost; Herbert Chen; John Bart Rose; Renata Jaskula-Sztul
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-23       Impact factor: 5.555

Review 4.  Modelling Pancreatic Neuroendocrine Cancer: From Bench Side to Clinic.

Authors:  Alexander Ney; Gabriele Canciani; J Justin Hsuan; Stephen P Pereira
Journal:  Cancers (Basel)       Date:  2020-10-28       Impact factor: 6.639

5.  A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor-guided antibody-drug conjugate: Perspectives on clinical response?

Authors:  Brendon Herring; Jason Whitt; Tolulope Aweda; Jianfa Ou; Rachael Guenter; Suzanne Lapi; Joel Berry; Herbert Chen; Xiaoguang Liu; J Bart Rose; Renata Jaskula-Sztul
Journal:  Surgery       Date:  2019-09-19       Impact factor: 3.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.